Roberto Gedaly, MD is a practicing transplant surgeon and clinician-scientist who has earned both national and international recognition for his work with infectious complications, including hepatitis, in-patients undergoing liver resection and liver transplantation. His research has focused upon immunosuppressive strategies in liver transplantation. His current research seeks to define markers and prognostic indicators of hepatocellular carcinoma in an attempt to determine more effective therapies. Doctor Gedaly is an Assistant Professor of Surgery within the University of Kentucky College of Medicine and is Chief of Transplantation at the University of Kentucky Chandler Medical Center. After receiving a medical degree from the Universidad Central de Venezuela in Caracas, Venezuela in 1990, Doctor Gedaly completed his general surgery residency at the University Hospital of Caracas. He then completed a two-year fellowship in hepatobiliary and transplantation service at Beth Israel Deaconess Medical Center through the Harvard Medical School in Boston, Massachusetts; a one-year fellowship in liver and GI transplantation at the Jackson Memorial Hospital at the University of Miami School of Medicine in Miami, Florida; and a two-year fellowship in transplantation at the Methodist University Hospital at the University of Tennessee School of Medicine. Doctor Gedaly joined the University of Kentucky in 2006. In addition to his clinical and administrative responsibilities as the Chief of Transplantation, he serves as a teacher and mentor to numerous medical students, interns and residents. He is actively engaged in medical and surgical societies, is a frequently invited guest speaker at meetings worldwide and has authored numerous publications appearing in leading peer-review journals and text books.
• Liver Transplantation
• Liver and Biliary Tract Surgery
• Kidney and Pancreas Transplant
1. Shu K Lui, V Vilchez and R Gedaly. Liver Cancer Stem Cells: A New Paradigm for Hepatocellular Carcinoma Treatment. J Stem Cell Res Ther, 2015, 5:5
2. C Coquillard MD, J Berger MD, M Daily MD, M Shah MD, X Mei PhD, F Marti PhD, R Gedaly MD. Combined Liver-Kidney Transplantation for Polycystic Liver and Kidney Disease: analysis from the UNOS dataset. Accepted Liver international.
3. L Garcia, J Berger, M Shah, M Daily, A Grigorian, P Hosein, R Gedaly, Liver Transplantation for Fibrolamellar Hepatocellular Carcinoma: a national perspective. Accepted for publication at HPB.
4. V Vilchez, M Daily, P Hosein, R Gedaly, E Maynard. Long-term Outcome of Patients Undergoing Liver Transplantation for Mixed Hepatocellulary Carcinoma and Cholangiocarcinoma: An Analysis of the UNOS Database. Accepted for publication at HBP
5. Sooyeon, K., Maynard, E. C., Shah, M. B., Daily, M. F., Tzeng, C.-W. D., Davenport, D. L., Gedaly, R. (November 20, 2013). Assessing 30-day Readmissions after Hepatectomy. Analysis of 2, 444 patients from the NSQIP Database. Liver Transplantation and Liver Surgery.
6. Patel, T., Dela Cruz, A. C., Sooyeon, K., Zanni, A., Esser, K. A., Gedaly, R. (November 20, 2013). Grip Strength is Significantly Reduced in Cirrhotic Patients Undergoing Transplant Evaluation wiht History of Smoking. Portal Hypertension and other Complications of Cirrhosis.
7. Galuppo, R. R., Gedaly, R., Angulo, P., Daily, M. F., Shah, M. B., Chen, C., Zhang, X., Esser, K., Evers, M., Jiang, J., Spear, B. T. (2013). Inhibits WNT/catenin signaling pathway in liver cancer stem cells and HCC cell lines. (58 (supp) ed., pp. 466A). Hepatology.
8. Angulo, P., Galuppo, R. R., Chen, C., Shah, M. B., Daily, M. F., Essers, M., Spear, B. T., Angulo, P., Gedaly, R. (2013). (2013). Synergistic inhibition of Liver Cancer Stem cells and HCC Cell lines targeting Wnt/B-catenin and Ras/Raf/MAPK pathways. (vol. 58 (supp), pp. 1071A). Hepatology.
9. Saliba, F., DeSimone, P. A., Nevens, F., De Carlis, L., Metselaar, H. J., Beckebaum, S., Jonas, S., Sudan, D., Fischer, L., Duvoux, C., Chavin, K. D., Koneru, B., Huang, M. A., Chapman, W. C., Foltys, D., Dong, G., Lopez, P. M., Fung, J., Junge, G., H2304 Study Group, Gedaly, R. (2013). Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. (7th ed., vol. 13, pp. 1734-45). Am J. Transplant. doi: 10.1111/ajt
10. Gedaly, R., Davenport, D. L., Daily, M. F., Shah, M. B., Hundley, J. C., Dagher, L., Angulo, P. (2012). Rising Incidence of Non-alcoholic Steatohepatitis (NASH) in Patients Transplanted for Hepatocelllar Carcinoma (HCC) in the United States. (4:40A ed., vol. 56).
11. Gedaly, R., Ranjan, D., Johnston, T. D., Jeon, H., Clifford, T. M. (2008). A Survey of Immunosuppressive Strategies in Liver Transplant Patients with Hepatitis C Virus. 2008 ACCP ANNUAL MEETING ABSTRACTS (vol. 29, pp. 180e). Boston, MA: PHARMACOTHERAPY. http://www.accp.com/docs/meetings/abstracts/2008_annual.pdf
12. Gedaly, R., Ranjan, D., Johnston, T. D., Jeon, H., Clifford, T. M. (2008). A Survey of Immunosuppressive Strategies in Liver Transplant Patients with Hepatitis C VirusAm J Transpl, (Supp 2 ed., vol. 8). http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2008.02255.x/pdf
13. Ranjan, D., Gedaly, R., Jeon, H., Johnston, T. D., Thompson, L. A., Clifford, T. M., McHugh, P. P. (2008). BASILIXIMAB INDUCTION IN ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS FOR DELAYED TACROLIMUS INITIATION AND RENAL PROTECTION (S1 ed., vol. 10). HPB. http://onlinelibrary.wiley.com/doi/10.1080/13651820701867935/pdf